tirzepatide fda indications is FDA-approved for weight management, with clinical trials showing average weight loss of 15–22.5% over 72 weeks. It's a prescription-only therapy, meaning it's not for everyone, and it works by acting FDA says shortage of GLP-1

However, the question of whether GLP-1 drugs might indirectly contribute to yeast infection risk requires nuanced consideration

10.3390/cells12091330 6 AlamM

Proper Technique for Administering Semaglutide Injections Sit comfortably and clean the injection site with an alcohol swab before administering semaglutide

Industry 2 min read Drug withdrawal rebound remains an unmet need in GLP-1R agonist space: GlobalData The rebound effect upon GLP-1R agonists withdrawal needs to be investigated further and new drug developments should aim to mitigate this big limitation and find ways in which GLP-1R agonists could be used as short-term therapies without causing weight regain and cardiometabolic risk reversal

Alruwaili H, Dehestani B, le Roux CW